



CLINICOPATHOLOGICAL ASSESSMENT OF BENIGN BREAST LESIONS IN A SAMPLE OF IRAQI PATIENTS

Rafal M. Jasim*¹ and Ban J. Qasim²

¹AL-Emamain Al-Kadhmain AS Medical City.

²Department of Pathology, College of Medicine, Al-Nahrain University. Baghdad Iraq.

Article Received date: 08 January 2024

Article Revised date: 28 January 2024

Article Accepted date: 18 February 2024



*Corresponding Author: Rafal M. Jasim

AL-Emamain Al-Kadhmain AS Medical City.

ABSTRACT

Introduction; Benign lesions are the most common cause of breast problems in females, they are 10 times more common than breast cancer in the western world and make up 90% of breast illnesses worldwide. **Method;** A retrospective study included an analysis of 200 cases of benign breast lesions, The clinic-pathological data that were collected from patient's pathology reports included age, laterality, quadrant, clinical presentation, site, and any associated incidental microscopic findings (UDH, ADH, DCIS, LCIS, and CA). **Results;** the mean age for diagnosing benign breast lesions is 32, fibroadenoma is the commonest lesion (38.5%) followed by fibrocystic changes (19.5%) and duct ectasia (12%), benign lesions are most commonly bilateral (46.5%) followed by right side (43%), (31%) of them are located in the upper outer quadrant and (72%) of them presented as a breast mass. **Conclusion;** Fibroadenoma followed by fibrocystic changes constitute the majority of benign breast lesions, they are most commonly bilateral, located in the upper outer quadrant and presented as a lump. There is a significant association between the histopathological diagnosis of a benign lesion with side, site and age of presentation.

INTRODUCTION

Benign lesions are the most common cause of breast problems in females; they are 10 times more common than breast cancer in the western world.^[1] And make up 90% of breast illnesses worldwide.^[2]

Based on the likelihood of developing breast cancer, benign epithelial lesions are categorized as proliferative and non-proliferative. Non-proliferative changes are not linked to a higher risk of breast cancer. A slight increase in the chance of developing cancer in either breast later on is linked to proliferative breast disease, which is characterized by the proliferation of epithelial cells without atypia.^[3]

Benign breast illnesses include developmental abnormalities, inflammatory lesions, epithelial and stromal proliferation, and neoplasms, including fibroadenomas, hyperplasia, intraductal papilloma, sclerosing adenosis, radial scars, fat necrosis, cysts, mastitis, duct ectasia, and granular cell tumors.^[4]

Pain and swelling are the most prevalent symptoms of these lesions.^[5] Clinical examination, mammography, ultrasound, and FNAC are simple methods for

diagnosing benign lesions, which can be confirmed through an excision biopsy or a core needle biopsy.^[6]

Millions of women worldwide are diagnosed with fibrocystic breast disease, the most prevalent benign form of breast illness. Up to 50% of women will experience symptoms at some point in their lives.^[7,8]

Fibroepithelial lesions are a distinct class of breast illnesses that share similar histologic characteristics but differ clinically. Examples of these lesions are fibroadenomas and phyllodes tumors. The most frequent benign breast mass is a fibroadenoma, while phyllodes tumors are less common and can be benign neoplasms or malignant tumors with the ability to spread to distant locations.^[9]

Breast fibroadenoma is a frequent biphasic tumor that peaks in occurrence in the second and third decades of life and affects women of all ages.^[10]

Breast sclerosing lesions known as radial scars are benign and are distinguished by a central fibroelastotic core with benign glands radiating from the center. Radial scars are benign but have an association with occult cancer, according to numerous studies.^[11]

Benign intraductal papilloma, the most common breast papillary lesion, has increased in incidence over the past 20 years, currently ranging from 1 to 9%.^[12,13]

Microglandular adenosis is a benign, poorly confined proliferation of glandular structures infiltrating breast stroma and adipose tissue, defying the "2-cell-type rule" for benign breast lesions.^[14]

The spectrum of benign spindle-cell breast lesions is broad and diverse, encompassing both myofibroblastic and fibroblastic lesions.^[15]

A benign mesenchymal breast lesion called pseudoangiomatous stromal hyperplasia is typified by myofibroblast growth that mimics a vascular lesion.^[16]

This study aims to assess benign breast lesions according to age, laterality, quadrant, clinical presentation, site, size, ultrasound findings, and any associated incidental microscopic findings (UDH, ADH, DCIS, LCIS and CA) among a sample of Iraqi women.

MATERIALS AND METHODS

A retrospective study included an analysis of 200 randomly selected cases of benign breast lesions collected from the Teaching Laboratories of Al-Emamain Al-Kadhmain Medical City (AS), Baghdad Medical City, from January 2022 to October 2023. The cases included 125 excisional biopsies, 47 core biopsies, and 28 trucut biopsies.

Hematoxylin and eosin-stained slides were collected, and the diagnosis was revised by two pathologists.

The clinic-pathological data that were collected from patient's pathology reports included age, laterality, quadrant, clinical presentation, site, and any associated incidental microscopic findings (UDH, ADH, DCIS, LCIS, and CA).

Exclusion Criteria

- Cases diagnosed with malignant neoplasms.
- Reports with incomplete clinical or pathological data.

All statistical analyses were performed utilizing SPSS version 26 and included mean, standard deviation, frequency, and percentage using Chi square, with a p-value <0.05 regarded as statistically significant.

RESULTS

The study sample

A total number of 200 patients were included in the study sample.

Age distribution of the studied sample

The age distribution of the studied sample ranged from 14 -57 years with a mean of 32.6 ± 10.7 SD. Regarding age group distribution, 83 (41.5%) patients were in the age group 14-30 years, 97 (48.5%) between 31-45 years, and 20 (10.0%) >45 years; as shown in figure (1).




Figure (1): Age distribution of the studied sample.

Clinical characteristics

Regarding affected side; most cases were on the right side (84.4%). Concerning the affected site, the upper outer quadrant was the most common (31.0%), followed by lower inner quadrant (22.5%). As for clinical presentation, most patients presented with breast mass

(72.5%); as shown in table (1).

Table (1): Clinical characteristics of the studied sample.

Variable	Frequency (N=200)	Percentage (%)
Affected side		
Right	86	84.4
Left	21	19.6
Affected site		
Upper inner	26	13.0
Lower inner	45	22.5
Upper outer	62	31.0
Lower outer	23	11.5
Areolar	38	19.0
Nipple	6	3.0
Clinical presentation		
Mass	145	72.5
Abscess	14	7.0
Calcification	12	6.0
Nipple discharge	13	6.5
Cysts of U/S	6	3.0
Densities on mammography	2	1.0
Galactorrhea	2	1.0
Nipple retraction	2	1.0
Skin bruising	2	1.0
Breast enlargement	2	1.0

Histopathological diagnosis

Regarding histopathological diagnosis; fibroadenoma (figure 2) was the most common diagnosis 38.5%,

followed by fibrocystic changes 19.5% (figure 3), duct ectasia 12.0% (figure 4) and intraductal papilloma 6% (figure 5); as shown in table (2).

Table (2): Distribution of cases according to histopathological diagnosis.

Variable	Frequency (N=200)	Percentage (%)
Fibroadenoma	77	38.5
Fibrocystic changes	39	19.5
Duct ectasia	24	12.0
Intraductal papilloma	12	6.0
Abscess	10	5.0
Fat necrosis	8	4.0
Chronic granulomatous mastitis	6	3.0
Cystic neutrophilic granulomatous	6	3.0
Adenosis with inflammation	4	2.0
Sclerosing adenosis	4	2.0
Apocrine metaplasia	4	2.0
Keratinous cyst	4	2.0
UDH	2	1.0
Total	200	100.0

Relationship between clinical parameters**Association between histopathological diagnosis and age**

A statistically significant association was detected between histopathological diagnosis and age (P value < 0.001); as shown in table (3).

Table (3): Association between histopathological diagnosis and age.

Histopathological diagnosis	Age			Total
	14-30 years	31-45 years	>45 years	
Fibroadenoma	59 76.6%	18 23.4%	0 0.0%	77 100.0%
Fibrocyastic changes	0 0.0%	37 94.9%	2 5.1%	39 100.0%
Ductectasia	6 25.0%	12 50.0%	6 25.0%	24 100.0%
Intraductal papilloma	6 50.0%	0 0.0%	6 50.0%	12 100.0%
Abcess	0 0.0%	10 100.0%	0 0.0%	10 100.0%
Fat necrosis	4 50.0%	4 50.0%	0 0.0%	8 100.0%
Chronic granulomatous mastitis	4 66.7%	2 33.3%	0 0.0%	6 100.0%
Cystic neutrophilic granulomatous	2 33.3%	4 66.7%	0 0.0%	6 100.0%
Adenosis with inflammation	0 0.0%	2 50.0%	2 50.0%	4 100.0%
Sclerosing adenosis	0 0.0%	2 50.0%	2 50.0%	4 100.0%
Apocrine metaplasia	0 0.0%	4 100.0%	0 0.0%	4 100.0%
Keratinous cyst	2 50.0%	2 50.0%	0 0.0%	4 100.0%
UDH	0 0.0%	0 0.0%	2 100.0%	2 100.0%
Total	83 41.5%	97 48.5%	20 10.0%	200 100.0%

Association between histopathological diagnosis and laterality

No statistically significant association was detected between histopathological diagnosis and laterality (P value = 0.092); as shown in table (4).

Table (4): Association between histopathological diagnosis and laterality.

Histopathological diagnosis	Laterality		Total
	Bilateral	Unilateral	
Fibroadenoma	37 48.1%	40 51.9%	77 100.0%
Fibrocyastic changes	20 51.3%	19 48.7%	39 100.0%
Ductectasia	8 33.3%	16 66.7%	24 100.0%
Intraductal papilloma	6 50.0%	6 50.0%	12 100.0%
Abcess	8 80.0%	2 20.0%	10 100.0%
Fat necrosis	2 25.0%	6 75.0%	8 100.0%
Chronic granulomatous mastitis	2 33.3%	4 66.7%	6 100.0%
Cystic neutrophilic granulomatous	2 33.3%	4 66.7%	6 100.0%
Adenosis with inflammation	0	4	4

	0.0%	100.0%	100.0%
Sclerosing adenosis	2	2	4
	50.0%	50.0%	100.0%
Apocrine metaplasia	2	2	4
	50.0%	50.0%	100.0%
Keratinous cyst	4	0	4
	100.0%	0.0%	100.0%
UDH	0	2	2
	0.0%	100.0%	100.0%
Total	93	107	200
	46.5%	53.5%	100.0%

Association between histopathological diagnosis and affected site

A statistically significant association was detected

between histopathological diagnosis and affected breast site (P value < 0.001); as shown in table (5).

Table (5): Association between histopathological diagnosis and affected breast site.

Histopathological diagnosis	Affected breast site						Total
	Upperinner	Lowerinner	Upperouter	Lowerouter	Areolar	Nipple	
Fibroadenoma	12	14	20	15	16	0	77
	15.6%	18.2%	26.0%	19.5%	20.8%	0.0%	100.0%
Fibrocystic changes	0	17	14	4	4	0	39
	0.0%	43.6%	35.9%	10.3%	10.3%	0.0%	100.0%
Ductectasia	6	4	4	0	6	4	24
	25.0%	16.7%	16.7%	0.0%	25.0%	16.7%	100.0%
Intraductal papilloma	2	4	2	2	0	2	12
	16.7%	33.3%	16.7%	16.7%	0.0%	16.7%	100.0%
Abscess	2	4	4	0	0	0	10
	20.0%	40.0%	40.0%	0.0%	0.0%	0.0%	100.0%
Fat necrosis	0	0	4	0	4	0	8
	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	100.0%
Chronic granulomatous mastitis	0	0	6	0	0	0	6
	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%	100.0%
Cystic neutrophilic granulomatous	2	0	0	2	2	0	6
	33.3%	0.0%	0.0%	33.3%	33.3%	0.0%	100.0%
Adenosis with inflammation	2	0	2	0	0	0	4
	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	100.0%
Sclerosing adenosis	0	0	2	0	2	0	4
	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	100.0%
Apocrine metaplasia	0	0	2	0	2	0	4
	0.0%	0.0%	50.0%	0.0%	50.0%	0.0%	100.0%
Keratinous cyst	0	2	2	0	0	0	4
	0.0%	50.0%	50.0%	0.0%	0.0%	0.0%	100.0%
UDH	0	0	0	0	2	0	2
	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	100.0%
Total	26	45	62	23	38	6	200
	13.0%	22.5%	31.0%	11.5%	19.0%	3.0%	100.0%

Association between histopathological diagnosis and associated diagnosis

No statistically significant association was detected between primary histopathological diagnosis and any associated diagnosis (P = 0.083); as shown in table (6).

Table (6): Association between histopathological diagnosis and associated diagnosis.

Histopathological diagnosis	Associated diagnosis				Total
	None	Adenosis	UDH	Atypical intraductal hyperplasia	
Fibroadenoma	60 77.9%	2 2.6%	9 11.7%	6 7.8%	77 100.0%
Fibrocyastic changes	37 94.9%	2 5.1%	0 0.0%	0 0.0%	39 100.0%
Ductectasia	24 100.0%	0 0.0%	0 0.0%	0 0.0%	24 100.0%
Intraductal papilloma	10 83.3%	2 16.7%	0 0.0%	0 0.0%	12 100.0%
Abcess	8 80.0%	0 0.0%	2 20.0%	0 0.0%	10 100.0%
Fat necrosis	8 100.0%	0 0.0%	0 0.0%	0 0.0%	8 100.0%
Chronic granulomatous mastitis	4 66.7%	2 33.3%	0 0.0%	0 0.0%	6 100.0%
Cystic neutrophilic granulomatous	6 100.0%	0 0.0%	0 0.0%	0 0.0%	6 100.0%
Adenosis with inflammation	4 100.0%	0 0.0%	0 0.0%	0 0.0%	4 100.0%
Sclerosing adenosis	4 100.0%	0 0.0%	0 0.0%	0 0.0%	4 100.0%
Apocrine metaplasia	4 100.0%	0 0.0%	0 0.0%	0 0.0%	4 100.0%
Keratinous cyst	4 100.0%	0 0.0%	0 0.0%	0 0.0%	4 100.0%
UDH	2 100.0%	0 0.0%	0 0.0%	0 0.0%	2 100.0%
Total	175 87.5%	8 4.0%	11 5.5%	6 3.0%	200 100.0%



Figure (2): fibroadenoma. The image shows the proliferation of benign mammary glands lined by epithelial and myoepithelial layers (red arrow) surrounded by the myxoid stroma (yellow arrow). (H&E, 20x).




Figure (3): fibrocystic change. The images show increased acini per lobule, cystically dilated benign ducts surrounded by fibrosis (A); the ducts show apocrine metaplasia (blue arrow). (B). (H&E, 10X, 20X).




Figure (4): ductectasia. The image shows dilated duct filled with macrophage (red arrow) and surrounded by fibrosis (blue arrow) and inflammation (yellow arrow). (H&E, 20X).




Figure (5): intraductal papilloma. The images show papillary proliferation within a dilated duct (A), the papillae have a fibrovascular core and lined by benign cuboidal cells (red arrow). (B). (H&E, 10X, 20X).

DISCUSSION

Overview; Given the widespread public awareness, women presenting with breast complaints—particularly lumps—are a regular finding and a major source of anxiety. Therefore, a surgeon's ability to differentiate benign from malignant illnesses and their frequency becomes crucial. Every year, 200,000 new cases of breast diseases are reported, with the majority of the palpable lesions being benign.^[17] A significant portion of research on benign breast diseases is concerned with how it may be related to the eventual development of cancer. Breast lesions with little to no increased risk of breast cancer should be identified from those with a little or moderate increase in risk and the classification of benign breast disease should take this stratification into account.^[18]

Regarding histopathological diagnosis; fibroadenoma was the most common diagnosis (38.5%) in this research, followed by fibrocystic changes (19.5%), duct ectasia (12.0%) and intraductal papilloma (6.0%) and other less frequent lesions.

These results are consistent with other studies like **ameet et al. (2022)**, which found Fibroadenoma (58.6%) was the commonest followed by Fibrocystic disease in (11.4%) of cases. (2) And **Kanpurwala et al. (2017)**, which mentioned that the commonest benign breast lesion was fibroadenoma (77.62%), followed by fibrocystic disease (4.3%).(1) While in another study conducted by **Nazma et al (2022)** most frequently encountered lesion was fibroadenoma (45.8%), breast abscess (22.6%) and fibrocystic change (11.6%).^[19]

Regarding age; the mean age in our study was 32, (48.5%) were between 31-45 years, (41.5%) patients were in the age group 14-30 years, and (10%) >45 years. And there was significant association between benign breast lesions and age.

According to **Mugdha et al. 2018**, The mean age of patients with benign breast lesions was 30 years.^[20] The majority of patients were between 31-40 years of age in a study by **Kotte Nagarjuna Reddy and G. Harshitha. (2022)**.^[21] both of these studies agree with ours, however (11-30) years was the commonest age group according to **Krishnareddy et al.**^[22] And was (21-30) according to **Sravanthi Kanumuri et al 2022.**^[23]

In this study, fibroadenoma had significantly higher rate in patients within the age group (14-30) while fibrocystic change was significantly higher in prevalence among patients (31-45) old.

This finding is comparable to other studies in the literature, like **Nazma et al. (2022)** and **Kumar N and Prasad J (2019)** where fibroadenoma was more frequent in the years 15-2.^[19,24] **Shweta Pai (2011)** and **Nazma et al. (2022)**, both studies found significantly higher prevalence of fibrocystic disease in third and fourth decades.^[25]

These findings are reasonable as fibrocystic changes are due to hormonal changes that occur during ovulation and just before menstruation; the breast cells that cause fibrocystic illness create cysts by retaining fluid.^[26] While fibroadenoma is more common in younger age group because breast fibroadenoma arises from lobules

that are more active and prone to growth during this period.^[27]

Regarding affected side; in the current study, most cases were on the right side (84.4%).

this aligns with other studies like **Abadi Venkat Reddy, 2019** and **Jetendra Yede et al, 2015**, who studied benign breast lesions and showed that right side was more common.^[28,29] the left side was most prevalent according to **Oluwole and Ajao, 1997**.^[30]

Regarding the affected quadrant; the upper outer quadrant was the most commonly affected side (31.0%), followed by lower inner quadrant (22.5%). Furthermore we found that the site of involvement was significantly associated with benign diagnoses.

this finding aligns with other studies in the literature like **Krishna Reddy et al. 2020**^[22] and **shobha et al 2016**.^[6] both reported the upper outer quadrant as the commonest site of involvement in benign breast lesions.

As for clinical presentation, most patients presented with breast mass (72.5%). Followed by abscess. (7), nipple discharge (6.5%) and calcification (6%) among other less prevalent symptoms according in our sample.

According to **Mallikarjuna et al.**, the most common symptom (80%) was the existence of a painless lump. According to **Sagar et al.**, 78.13% of cases had a painless lump.^[31,32] The clinical presentation was mainly also a painless lump according to **Krishna Reddy et al.**,^[22] **Jetendra et al.**,^[29] and **Abadi Venkat Mohan Reddy**.^[33]

Out of 200 cases, in the present study, adenosis was found in 8 cases (2 in chronic granulomatous mastitis, 2 of papillomas, 2 in fibrocystic disease cases and 2 in fibroadenomas), UDH was present in 11 of cases (2 within abscess cases and 9 within fibroadenoma cases), ADH was detected in 6 cases (3%), all of them were within fibroadenomas. However there was no significant association between the associated/ incidental finding and the histopathological diagnosis.

Atypical hyperplasia was found in just 4% of the biopsy samples in a study conducted by **(Dupont and Page 2010)**.^[34] 4.6% of cases had ADH according to **(Mima Maychet B. and Sangma 2013)**.^[35] Our study's results were close to the above investigations. Our sample, however, was fewer in quantity than theirs.

CONCLUSION

Benign breast lesions constitute a heterogeneous group of diseases, fibroadenoma followed by fibrocystic changes constitute the majority of them, they are most commonly bilateral, located in the upper outer quadrant and presented as a lump. There is a significant association between the histopathological diagnosis of a

benign lesion with side, site and age of presentation.

REFERENCES

1. Kanpurwala Shaheen Hatim, Narayankar Shilpa Laxmikant, Mulla T. Patterns and prevalence of benign breast disease in Western India. *International Journal of Research in Medical Sciences*, 2017 Jan 23; 5(2): 684–4.
2. Kaur A, Kour B, Bhardwaj S. A STUDY OF HISTOPATHOLOGICAL SPECTRUM OF BENIGN BREAST DISEASES - A TWO YEAR RETROSPECTIVE ANALYSIS. *International Journal of Advanced Research*, 2020 Apr 30; 8(4): 683–8.
3. Ramesh K, Kishan Bookya. A study on clinical and pathological correlation of benign breast lesions. *International Surgery Journal*, 2017 Jul 24; 4(8): 2700–0.
4. Derkyi-Kwarteng L, A. Brown A, Derkyi-Kwarteng A, Gyan E, P. Akakpo K, Abraham A. Benign Proliferative Breast Disease: A Histopathological Review of Cases at Korle Bu Teaching Hospital. *Journal of Advances in Medicine and Medical Research*, 2020 Jan 23; 1.
5. Chaudhary M, Bhat P, Wankhede V, Aagja J, Rathva D, Ahir T. Clinicopathological study of benign breast diseases a study of 50 cases. *International Surgery Journal*, 2021 Apr 28; 8(5): 1462.
6. M DrV, Rao DrJY, Shekar DrTY, Balakrishnan DrS, M DrD, K DrS, et al. Prevalence of Benign Breast Disease and Risk of Malignancy in Benign Breast Diseases. *IOSR Journal of Dental and Medical Sciences*, 2016 Aug; 15(08): 32–6.
7. Malherbe K, Fatima S. Fibrocystic Breast Disease [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing, 2021. Available from: <https://pubmed.ncbi.nlm.nih.gov/31869073/>
8. Faguy K. Fibrocystic Breast Changes. *Radiologic Technology* [Internet], 2022 Jan 1; 93(3): 303M315M. Available from: <https://pubmed.ncbi.nlm.nih.gov/35017277/>
9. Fraker JL, Clune CG, Sahni S, Avani Yaganti, Suneela Vegunta. Prevalence, Impact, and Diagnostic Challenges of Benign Breast Disease: A Narrative Review. *International Journal of Women's Health*, 2023 May 1; 15: 765–78.
10. Begum Z, Tengli M, Mahantappa S, Farheen, Lateef A, Student P. Histomorphological study of various patterns in breast lesions, including carcinoma breast. *Indian Journal of Pathology and Oncology* [Internet], 2017 [cited 2023 Dec 5]; 4(2): 301–7. Available from: <https://www.ijpo.co.in/article-download/full-text/4222>
11. Aparna Harbhajanka, Gilmore H, Calhoun BC. High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision. *Modern Pathology*, 2022 Nov 1; 35(11): 1500–8.
12. Rasmussen BB, Balslev E, Jarle Christensen I,

- Lanng C, Bak A, Galatius H, et al. Diagnostic challenges in clinical, radiological and histopathological tests regarding papillomatous lesions of the breast. *The Breast*, 2018 Aug; 40: 177–80.
13. Rakha EA, Ellis IO. Diagnostic challenges in papillary lesions of the breast. *Pathology*, 2018 Jan; 50(1): 100–10.
 14. Foschini MP, Eusebi V. Microglandular adenosis of the breast: a deceptive and still mysterious benign lesion. *Human Pathology*, 2018 Dec; 82: 1–9.
 15. Magro G. Differential Diagnosis of Benign Spindle Cell Lesions. *Surgical Pathology Clinics*, 2018 Mar; 11(1): 91–121.
 16. Estes A, Cao L, Miller ME. Pseudoangiomatous stromal hyperplasia: overview and clinical management. *Annals of Breast Surgery*, 2020 Dec; 4: 22–2.
 17. Profile of Breast Diseases in Post Pubertal Women Assessed By Clinical Breast Examination - A Community Based Study in Rural Pondicherry Kavasseri L Janaki 1, Narayanasamy Subbaraju Kannan 2, M Palaniappan 3, Partha Nandi.
 18. Maldonado-Martinez HA, Perez-Sanchez VM, Sanchez CHC, Juarez-Sanchez P, Meneses-Garcia A. Benign breast diseases: Current pathological and molecular concepts. *Benign Dis Breast Diagnosis Treat*, 2014; (April): 249–305.
 19. Kiran N, Henna N, Gohier A, Aslam N, Javaid MF, Akhter N. Spectrum of Benign Breast Diseases in Surgically Excised Specimens: A Clinicopathological Study. *Pakistan J Med Heal Sci.*, 2022; 16(6): 59–61.
 20. Khanam KF, Akter N, Tabashum T, Raza AKMM, Hosna AU, Rahman F, et al. A Clinicopathologic Study of Various Breast Lesions by Fine Needle Aspiration Cytology (FNAC). *J Curr Surg*, 2018; 8(3–4): 27–31.
 21. Clinical study on benign breast diseases Kotte Nagarjuna Reddy, G. Harshitha.
 22. A study on clinical profile of Benign Breast lesions Author(s): Krishnareddy Y Navalli, Mohammed Faheem Inamdar and Sunil R Telkar.
 23. Kanumuri S, Chalamalasetty JD, Reddy AS, Punyapu S, Damam R, Sri NVSL. A study of benign breast disease management based on clinical, radiological and pathological assessment. *Sci Med Sci.*, 2022; 2(2(47)): 11–6.
 24. Kumar N, Prasad J. Epidemiology of benign breast lumps, is it changing: a prospective study. *Int Surg J.*, 2019; 6(2): 465.
 25. Pai S. The spectrum of benign breast diseases among females: A 6-year histopathological study. *Indian J Pathol Oncol*, 2019; 6(4): 561–7.
 26. Kumbhakar D, Talukdar PP. Histopathological Patterns of Breast Lesions - A Hospital-Based Study. *J Evid Based Med Healthc*, 2021; 8(10): 567–74.
 27. Review on Fibroadenoma S. Verma, Abhinandan Gupta Huang Yuan Yi Published, 24 May 2019.
 28. Mohan Reddy DAV. The spectrum of benign breast lesions – A study in Tertiary Care Hospital. *J Med Sci Clin Res.*, 2019; 7(11): 872–6.
 29. Clinical presentation, imaging, pathological profile and management of benign breast conditions based on aberrations of normal development and involution classification: A prospective cohort study Jetendra Yede, Nitin Wasnik, Vijay P Agrawal, Murtaza A Ak.
 30. Ajao OG. Benign breast lesions. *Journal of the National Medical Association [Internet]*. 1979 [cited 2024 Jan 28]; 71(9): 867–8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2537488/>.
 31. Mallikarjuna, Maralihalli SS. Clinico-pathological study of benign breast disease, 2015; 4(2): 39-46.
 32. Sagar R, Gaddikeri P, Ramakrishna MK. Analytical study of pattern and presentation of benign breast diseases in patients between age group 15 to 35 years. *Int J Biomed Res.*, 2015; 6(6): 412-5.
 33. The spectrum of benign breast lesions – A study in Tertiary Care Hospital Abbadi Venkat Mohan Reddy.
 34. Risk factors for BC in women with proliferative breast disease. *N Engl J Med.*, 2010.
 35. Sangma MMB, Panda K, Dasiah S. A clinico-pathological study on benign breast diseases. *J Clin Diagnostic Res.*, 2013; 7(3): 503–6.